Ocriplasmin for symptomatic vitreomacular adhesion: An evidence-based review of its potential

Su Jeong Song, William E Smiddy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss. This has been especially important since for many years, the only treatment option involved surgical intervention (vitrectomy) to release the persistent VMA. Recently, a pharmacolytic agent, ocriplasmin, has become available after many years of development and investigation, and may offer a feasible alternative to surgery, or even a risk/benefit ratio sufficiently favorable to offer intervention at an earlier stage of VMA. Several studies, including a large, prospective clinical trial, have established the foundation of its rationale and efficacy, providing the basis of its approval. The role for ocriplasmin in clinical practice is in the process of being determined. This paper summarizes current knowledge and status of investigations regarding ocriplasmin-induced pharmacologic vitreolysis, and offers some evidence-based considerations for its use.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalCore Evidence
Volume9
DOIs
StatePublished - Mar 21 2014

Fingerprint

Traction
Optical Tomography
Retinal Perforations
Vitrectomy
Odds Ratio
Clinical Trials
microplasmin
Therapeutics

Keywords

  • Macular edema
  • Microplasmin
  • Pharmacologic vitreolysis
  • Posterior vitreous detachment

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Reviews and References, Medical

Cite this

Ocriplasmin for symptomatic vitreomacular adhesion : An evidence-based review of its potential. / Song, Su Jeong; Smiddy, William E.

In: Core Evidence, Vol. 9, 21.03.2014, p. 51-58.

Research output: Contribution to journalArticle

@article{d54650f6b88c44db9bd23c8ad2a9a33f,
title = "Ocriplasmin for symptomatic vitreomacular adhesion: An evidence-based review of its potential",
abstract = "Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss. This has been especially important since for many years, the only treatment option involved surgical intervention (vitrectomy) to release the persistent VMA. Recently, a pharmacolytic agent, ocriplasmin, has become available after many years of development and investigation, and may offer a feasible alternative to surgery, or even a risk/benefit ratio sufficiently favorable to offer intervention at an earlier stage of VMA. Several studies, including a large, prospective clinical trial, have established the foundation of its rationale and efficacy, providing the basis of its approval. The role for ocriplasmin in clinical practice is in the process of being determined. This paper summarizes current knowledge and status of investigations regarding ocriplasmin-induced pharmacologic vitreolysis, and offers some evidence-based considerations for its use.",
keywords = "Macular edema, Microplasmin, Pharmacologic vitreolysis, Posterior vitreous detachment",
author = "Song, {Su Jeong} and Smiddy, {William E}",
year = "2014",
month = "3",
day = "21",
doi = "10.2147/CE.S39363",
language = "English",
volume = "9",
pages = "51--58",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ocriplasmin for symptomatic vitreomacular adhesion

T2 - An evidence-based review of its potential

AU - Song, Su Jeong

AU - Smiddy, William E

PY - 2014/3/21

Y1 - 2014/3/21

N2 - Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss. This has been especially important since for many years, the only treatment option involved surgical intervention (vitrectomy) to release the persistent VMA. Recently, a pharmacolytic agent, ocriplasmin, has become available after many years of development and investigation, and may offer a feasible alternative to surgery, or even a risk/benefit ratio sufficiently favorable to offer intervention at an earlier stage of VMA. Several studies, including a large, prospective clinical trial, have established the foundation of its rationale and efficacy, providing the basis of its approval. The role for ocriplasmin in clinical practice is in the process of being determined. This paper summarizes current knowledge and status of investigations regarding ocriplasmin-induced pharmacologic vitreolysis, and offers some evidence-based considerations for its use.

AB - Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss. This has been especially important since for many years, the only treatment option involved surgical intervention (vitrectomy) to release the persistent VMA. Recently, a pharmacolytic agent, ocriplasmin, has become available after many years of development and investigation, and may offer a feasible alternative to surgery, or even a risk/benefit ratio sufficiently favorable to offer intervention at an earlier stage of VMA. Several studies, including a large, prospective clinical trial, have established the foundation of its rationale and efficacy, providing the basis of its approval. The role for ocriplasmin in clinical practice is in the process of being determined. This paper summarizes current knowledge and status of investigations regarding ocriplasmin-induced pharmacologic vitreolysis, and offers some evidence-based considerations for its use.

KW - Macular edema

KW - Microplasmin

KW - Pharmacologic vitreolysis

KW - Posterior vitreous detachment

UR - http://www.scopus.com/inward/record.url?scp=84897529154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897529154&partnerID=8YFLogxK

U2 - 10.2147/CE.S39363

DO - 10.2147/CE.S39363

M3 - Article

AN - SCOPUS:84897529154

VL - 9

SP - 51

EP - 58

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

ER -